This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...

The CBGM sensor lead was placed intravascularly ... This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

The CBGM sensor lead was placed intravascularly via a percutaneous ... This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on ...

This study represents first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Zach began writing for CNET in November, 2021 after writing for a broadcast news station in his hometown, Cincinnati, for five years. You can usually find him reading and drinking coffee or ...

Glucotrack (Nasdaq:GCTK) today said it hit a significant milestone in the development of its continuous blood glucose monitor (CBGM). Our sister site, Drug Delivery Business News, reports today ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose monitor (CBGM). The study included participants with both type 1 and type 2 ...